Please ensure Javascript is enabled for purposes of website accessibility

2 Healthcare Stocks to Buy This Week

By George Budwell - Updated Apr 14, 2019 at 9:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of Amarin and Neptune Wellness Solutions could be stellar buys this week. Here's why.

Healthcare stocks, like most of this chaotic market, kicked off the new year with a volatile first week of trading. While the overall trend was positive last week, healthcare investors shouldn't necessarily take this early momentum too seriously. The overall market, after all, remains very much in flux at the moment due to an abundance of headwinds, such as rising interest rates, political turmoil, and the ongoing trade war. 

That being said, there are a select few healthcare stocks actually worth buying heading into the second week of trading. Amarin (AMRN 2.17%) and Neptune Wellness Solutions (NEPT 11.97%), for example, are both tremendous bargains at current levels. Read on to find out more about these two promising healthcare growth stocks. 

A man in a suit holding yellow wooden blocks that spell buy in red letters.

Image source: Getty Images.

The bottom is near

Check out the latest Amarin earnings call transcript.

Amarin, an Irish biopharma that markets a prescription fish oil medication called Vascepa, drew the ire of investors in after-market trading last week by releasing a softer-than-expected earnings forecast for 2019. In fact, the drugmaker's shares dropped by a staggering 7% immediately after this new hit the wires last Friday. As a result, Amarin's shares have now lost close to 50% of their value since hitting an all-time high only a few months ago. 

Although investors were anticipating a breakout year for Vascepa due to the drug's positive cardiovascular outcome trial results released in late 2018, management decided to downplay that trial's impact on the drug's near-term commercial trajectory. Specifically, Amarin stated that its 2019 sales will come in at around $350 million -- a figure that is well below Wall Street's consensus estimate of $417.5 million.  

Why the marked discrepancy? In their initial earnings guidance for the year, management argued that investors shouldn't expect a major bump in revenue until after Vascepa's label is officially expanded by the Food and Drug Administration -- an event that probably won't take place until next year. Wall Street, on the other hand, clearly thinks that doctors will begin to prescribe the drug off-label, presumably because of its demonstrated cardiovascular benefit in patients with persistently high triglyceride levels, despite being on statin therapy. 

The good news for investors is that management appears to be issuing an underwhelming guidance mostly for strategic purposes. Vascepa's sales, after all, have already started to pick up in a big way in recent weeks and there's no reason to believe this noteworthy uptick will suddenly flatten out. 

All in all, Amarin's dramatic decline over the past few months seems to be close to an end, given the company's exceptional outlook moving forward.  

An emerging cannabis play

Check out the latest Neptune Wellness Solutions earnings call transcript.

Over the course of 2018, most cannabis companies underwent a radical metamorphosis, thanks to the legalization of recreational marijuana in Canada, the steady march toward widespread legalization in the United States, Mexico, and several other key geographies, as well as the passage of the 2018 farm bill that legalized low-THC products such as hemp and cannabidiol (CBD) oils. 

In a move to capitalize on this rising tide, Neptune Wellness Solutions decided to abruptly change its core focus by launching a cannabis extract supply business last year. As part of this transition away from so-called nutraceuticals (foods with medical benefits) and toward cannabis extracts, the company signed partnership agreements with both Canopy Growth and Tetra Bio-Pharma in 2018. This change of heart could turn out to be an extremely smart move by Neptune. Brightfield Group, a top cannabis industry analyst group, after all, believes CBD oils can grow into a $22 billion-a-year marketplace, after all. 

Even so, Neptune's stock has struggled mightily over the past few months due to the prolonged wait for a marijuana processing license from Health Canada. But the wait may finally be over.

According to Health Canada's website, Neptune's subsidiary, 9354-7537 Quebec Inc., was granted a processing license last Friday. While the company has yet to confirm this game-changing news, investors are already bidding up Neptune's stock. In after-hours trading last Friday, for instance, Neptune's shares rose by as much as 21%, and they are currently up by more than 12% in pre-market trading today. 

All told, Neptune's pivot to cannabis appears to be taking shape with this key regulatory headwind out of the way, which should help its stock rebound in the days and weeks ahead. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.65 (2.17%) $0.04
Neptune Wellness Solutions Inc. Stock Quote
Neptune Wellness Solutions Inc.
NEPT
$1.59 (11.97%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.